Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Is Low Positive JAK2 Multi-Institutional Study

Is Low Positive JAK2 Multi-Institutional Study RESEARCH ARTICLE Is Low Positive JAK2 V617F Mutation Test Result Clinically Significant?: Multi-Institutional Study Xiaojun Wu, MD, PhD,* Joong Won Lee, MD,w Deniz Peker, MD,* Silvia G. Spitzer, PhD,w Jordan Laser, MD,w Vishnu V.B. Reddy, MD,* and Shuko Harada, MD* by hypersensitivity of hematopoietic progenitors to nu- Objectives: Acquired somatic mutation Janus kinase 2 (JAK2) merous cytokines and clonal proliferation of one or more V617F is associated with various myeloproliferative neoplasms 1 myeloid lineages. Chronic myelogenous leukemia (MPN). Allele-specific real-time polymerase chain reaction has been (CML), polycythemia vera (PV), essential thrombocy- widely adopted to detect mutation; however, the utility of low thaemia (ET), and primary myelofibrosis (PMF) are the positive results is not well understood. The aim of this study is to commonly seen types of MPN. Janus kinase 2 (JAK2)is a investigate the clinical significance of low positivity of JAK2 V617F. cytoplasmic tyrosine kinase that mediates growth factor receptor signaling. The valine to phenylalanine substitution Materials and Methods: Retrospective analysis was performed for at amino acid 617 (V617F) in exon 14 causes a disruption JAK2 V617F mutation tests performed using JAK2 MutaQuant of the autoinhibitory JH2 domain, which results in con- kit (Ipsogen) in molecular laboratories at 2 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Is Low Positive JAK2 Multi-Institutional Study

Harada, Shuko
Applied Immunohistochemistry & Molecular Morphology , Volume Publish Ahead of Print – Sep 1, 2015
Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/is-low-positive-jak2-multi-institutional-study-RkQzsI00I7

References (25)

Copyright
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1541-2016
DOI
10.1097/PAI.0000000000000228
pmid
26371429
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE Is Low Positive JAK2 V617F Mutation Test Result Clinically Significant?: Multi-Institutional Study Xiaojun Wu, MD, PhD,* Joong Won Lee, MD,w Deniz Peker, MD,* Silvia G. Spitzer, PhD,w Jordan Laser, MD,w Vishnu V.B. Reddy, MD,* and Shuko Harada, MD* by hypersensitivity of hematopoietic progenitors to nu- Objectives: Acquired somatic mutation Janus kinase 2 (JAK2) merous cytokines and clonal proliferation of one or more V617F is associated with various myeloproliferative neoplasms 1 myeloid lineages. Chronic myelogenous leukemia (MPN). Allele-specific real-time polymerase chain reaction has been (CML), polycythemia vera (PV), essential thrombocy- widely adopted to detect mutation; however, the utility of low thaemia (ET), and primary myelofibrosis (PMF) are the positive results is not well understood. The aim of this study is to commonly seen types of MPN. Janus kinase 2 (JAK2)is a investigate the clinical significance of low positivity of JAK2 V617F. cytoplasmic tyrosine kinase that mediates growth factor receptor signaling. The valine to phenylalanine substitution Materials and Methods: Retrospective analysis was performed for at amino acid 617 (V617F) in exon 14 causes a disruption JAK2 V617F mutation tests performed using JAK2 MutaQuant of the autoinhibitory JH2 domain, which results in con- kit (Ipsogen) in molecular laboratories at 2

Journal

Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health

Published: Sep 1, 2015

There are no references for this article.